

EMA/315803/2021

European Medicines Agency decision P/0265/2021

of 7 July 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous selected renal cells (EMA-002844-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0265/2021

of 7 July 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous selected renal cells (EMA-002844-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by inRegen on 10 August 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 May 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for autologous selected renal cells, suspension for injection, percutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for autologous selected renal cells, suspension for injection, percutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for autologous selected renal cells, suspension for injection, percutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to ProKidney, 10 Market Street, # 688 Camana Bay, KY1-9006 - Grand Cayman, Cayman Isds.

EMA/PDCO/120032/2021 **corr**
Amsterdam, 21 May 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002844-PIP01-20

Scope of the application

Active substance(s):

Autologous selected renal cells

Condition(s):

Treatment of chronic kidney disease

Pharmaceutical form(s):

Suspension for injection

Route(s) of administration:

Percutaneous use

Name/corporate name of the PIP applicant:

ProKidney

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, inRegen submitted for agreement to the European Medicines Agency on 10 August 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 September 2020.

On 12 February 2021 inRegen requested to transfer the paediatric investigation plan to ProKidney.

Supplementary information was provided by the applicant on 12 February 2021. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation;
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic kidney disease (CKD)

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- suspension for injection, percutaneous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition:

Treatment of chronic kidney disease

2.1.1. Indication(s) targeted by the PIP

Treatment of patients with progressive chronic kidney disease resulting from congenital anomalies of the kidney and urinary tract (CAKUT) aged 2 years to less than 18 years

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Suspension for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	2	Study 1 (REGEN-005) Open-label, single-arm study to investigate the safety, tolerability, and effectiveness of renal autologous cell therapy (REACT) in children and adolescents from 2 years to less than 18 years of age with CKD Study 2 (REGEN-011) Open-label, dual-arm study to investigate the safety and efficacy of REACT in terms of superiority versus standard-

		of-care (SOC) in children and adolescents from 2 years to less than 18 years of age with CKD
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2034
Deferral for one or more measures contained in the paediatric investigation plan:	Yes